In this video, Dr Mona Shahriari, dermatologist and Assistant Clinical Professor at Yale University, explores tapinarof cream 1%, or VTAMA, a novel topical treatment for plaque psoriasis. She discusses VTAMA's unique mechanism as an aryl hydrocarbon receptor agonist, which specifically targets key pathways involved in psoriasis—reducing inflammation and oxidative stress and improving skin barrier function.

Dr Shahriari reviews VTAMA alongside traditional corticosteroids, highlighting its lack of systemic side effects, absence of usage restrictions, and suitability for sensitive skin areas. Dr Shahriari also details VTAMA’s accessibility, including the patient savings program. Watch the full video to see why Dr Shahriari considers VTAMA a new standard in psoriasis care, offering patients a powerful option for managing their condition.

IMPORTANT SAFETY INFORMATION

VTAMA cream is for use on the skin (topical) only. Do not use VTAMA cream in your eyes, mouth, or vagina. Adverse Events: The most common adverse reactions (incidence ≥ 1%) in subjects treated with VTAMA cream were folliculitis (red raised bumps around the hair pores), nasopharyngitis (pain or swelling in the nose and throat), contact dermatitis (skin rash or irritation, including itching and redness, peeling, burning, or stinging), headache, pruritus (itching), and influenza (flu). Indication: VTAMA^® (tapinarof) cream, 1% is an aryl hydrocarbon receptor agonist indicated for the topical treatment of plaque psoriasis in adults.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.